EGFR‐TKI plus antiangiogenic agent combination therapy may reduce the incidence of EGFR‐TKI–associated interstitial lung disease in Asian

• Tai‐Huang Lee,
• Hsiao‐Ling Chen,
• Ming‐Ju Tsai,
• Chih‐Jen Yang

Affiliations

Tai‐Huang Lee

Department of Internal Medicine Kaohsiung Municipal Ta‐Tung Hospital Kaohsiung Taiwan

Hsiao‐Ling Chen

Department of Pharmacy Kaohsiung Municipal Ta‐Tung Hospital Kaohsiung Taiwan

Ming‐Ju Tsai

Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine Kaohsiung Medical University Hospital Kaohsiung Taiwan

Chih‐Jen Yang

Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine Kaohsiung Medical University Hospital Kaohsiung Taiwan